More importantly, these studies also confirmed the effectiveness of neuraminidase inhibitor oseltamivir in reducing platelet destruction in vivo in the setting of anti-GPIIb/IIIa antibodies-mediated ITP [37,38], providing further evidence that both anti-GPIb/IX and anti-GPIIb/IIIa antibodies may lead to platelet desialylation. Here, ITGA2B is linked to autoimmune thrombocytopenic purpura.